(S)-N-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-2-((hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)thiazole-4-carboxamide | 1309784-72-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (S)-N-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-2-((hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)thiazole-4-carboxamide
• 英文别名: 2-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylmethyl]-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-1,3-thiazole-4-carboxamide；2-[[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]methyl]-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-1,3-thiazole-4-carboxamide
• CAS: 1309784-72-2
• 化学式: C₂₇H₂₇N₇OS
• 分子量: 497.624
• InChiKey: ZLUJHZLLTJYOKN-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(chloromethyl)-N-[6-(1H-indol-4-yl)-1-(phenylsulfonyl)-1H-indazol-4-yl]-1,3-thiazole-4-carboxamide 在 N,N-二异丙基乙胺 、 sodium iodide 、 sodium hydroxide 作用下， 以 水 、 异丙醇 、 乙腈 为溶剂， 反应 31.25h， 生成 (S)-N-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-2-((hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)thiazole-4-carboxamide
  参考文献：
  名称：

  Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease

  摘要：

  Optimization of lead compound 1, through extensive use of structure-based design and a focus on PI3K delta potency, isoform selectivity, and inhaled PK properties, led to the discovery of clinical candidates 2 (GSK2269557) and 3 (G5K2292767) for the treatment of respiratory indications via inhalation. Compounds 2 and 3 are both highly selective for PI3K delta over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.

  DOI：

  10.1021/acs.jmedchem.5b00767

文献信息

• Use of Inhibitors of the Activity or Function of PI3K
  申请人：NOVARTIS AG

  公开号：US20150342951A1

  公开（公告）日：2015-12-03

  The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

  该发明涉及PI3K抑制剂的新用途，其中所述抑制剂对PI3K同工酶δ具有抑制作用，用于治疗患有疟疾、利什曼病、锥虫病、弓形虫病和/或神经囊虫病等疾病或紊乱的受试者的免疫病理学，通过对感染受试者的TLR9的功能抑制。
• [EN] BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES<br/>[FR] DÉRIVÉS DE BENZPYRAZOLE COMME INHIBITEURS DES PI3 KINASES
  申请人：GLAXO GROUP LTD

  公开号：WO2011067365A1

  公开（公告）日：2011-06-09

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

  这项发明涉及某些新颖化合物。具体来说，该发明涉及式(I)的化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。
• BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES
  申请人：Baldwin Ian Robert

  公开号：US20120245171A1

  公开（公告）日：2012-09-27

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

  本发明涉及某些新型化合物。具体而言，本发明涉及公式(I)的化合物及其盐。本发明的化合物是PI3-激酶活性抑制剂。
• BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES
  申请人：Glaxo Group Limited

  公开号：EP2507223A1

  公开（公告）日：2012-10-10
• US9949979B2
  申请人：——

  公开号：US9949979B2

  公开（公告）日：2018-04-24